Semaglutide (Wegovy) and liraglutide (Saxenda) are recommended within specialist weight management services for adults with a BMI of at least 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity
"These medications are powerful tools, but they're not magic," he says
For people who do not have diabetes, only semaglutide was associated with a reduction in depression and anxiety, compared to people who were not on GLP-1 medications
No matter your BMI, whether or not you had diabetes, we saw the beneficial effects of greater sensitivity for reducing the risk of outcomes in all subgroups, Hung said